Nektar Therapeutics (NKTR)

$1.38

+0.01

(+0.73%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.31
    $1.41
    $1.38
    downward going graph

    5.07%

    Downside

    Day's Volatility :6.76%

    Upside

    1.78%

    downward going graph
  • $0.41
    $1.93
    $1.38
    downward going graph

    70.1%

    Downside

    52 Weeks Volatility :78.62%

    Upside

    28.5%

    downward going graph

Returns

PeriodNektar TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
3.79%
6.5%
0.0%
6 Months
169.16%
7.1%
0.0%
1 Year
155.6%
9.8%
0.0%
3 Years
-91.56%
14.2%
-20.2%

Highlights

Market Capitalization
259.5M
Book Value
$0.69
Earnings Per Share (EPS)
-0.91
PEG Ratio
3.22
Wall Street Target Price
1.6
Profit Margin
-195.02%
Operating Margin TTM
-159.21%
Return On Assets TTM
-17.31%
Return On Equity TTM
-95.68%
Revenue TTM
90.2M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
0.2%
Gross Profit TTM
70.4M
EBITDA
-125.5M
Diluted Eps TTM
-0.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.81
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Hold
    0
    0%Buy
    55%Hold
    44%Sell
Based on 9 Wall street analysts offering stock ratings for Nektar Therapeutics(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
5
5
6
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 15.94%

Current $1.38
Target $1.60

Company Financials

FY18Y/Y Change
Revenue
1.2B
↑ 287.81%
Net Income
681.3M
↓ 804.62%
Net Profit Margin
57.09%
↑ 88.51%
FY19Y/Y Change
Revenue
114.6M
↓ 90.4%
Net Income
-440.7M
↓ 164.68%
Net Profit Margin
-384.47%
↓ 441.56%
FY20Y/Y Change
Revenue
152.9M
↑ 33.41%
Net Income
-444.4M
↑ 0.86%
Net Profit Margin
-290.65%
↑ 93.82%
FY21Y/Y Change
Revenue
101.9M
↓ 33.36%
Net Income
-523.8M
↑ 17.86%
Net Profit Margin
-514.03%
↓ 223.38%
FY22Y/Y Change
Revenue
92.1M
↓ 9.67%
Net Income
-368.2M
↓ 29.71%
Net Profit Margin
-399.98%
↑ 114.05%
FY23Y/Y Change
Revenue
90.1M
↓ 2.1%
Net Income
-276.1M
↓ 25.03%
Net Profit Margin
-306.31%
↑ 93.67%
Q4 FY22Q/Q Change
Revenue
22.0M
↓ 6.78%
Net Income
-59.7M
↑ 1.08%
Net Profit Margin
-271.03%
↓ 21.09%
Q1 FY23Q/Q Change
Revenue
21.6M
↓ 1.95%
Net Income
-137.0M
↑ 129.56%
Net Profit Margin
-634.52%
↓ 363.49%
Q2 FY23Q/Q Change
Revenue
20.5M
↓ 5.07%
Net Income
-51.1M
↓ 62.69%
Net Profit Margin
-249.39%
↑ 385.13%
Q3 FY23Q/Q Change
Revenue
24.1M
↑ 17.78%
Net Income
-45.8M
↓ 10.34%
Net Profit Margin
-189.85%
↑ 59.54%
Q4 FY23Q/Q Change
Revenue
23.9M
↓ 1.07%
Net Income
-42.1M
↓ 8.2%
Net Profit Margin
-176.17%
↑ 13.68%
Q1 FY24Q/Q Change
Revenue
21.6M
↓ 9.4%
Net Income
-36.8M
↓ 12.54%
Net Profit Margin
-170.07%
↑ 6.1%
FY18Y/Y Change
Total Assets
2.2B
↑ 322.54%
Total Liabilities
432.6M
↑ 2.75%
FY19Y/Y Change
Total Assets
2.0B
↓ 8.04%
Total Liabilities
572.0M
↑ 32.22%
FY20Y/Y Change
Total Assets
1.5B
↓ 22.18%
Total Liabilities
461.5M
↓ 19.32%
FY21Y/Y Change
Total Assets
1.1B
↓ 27.4%
Total Liabilities
437.7M
↓ 5.16%
FY22Y/Y Change
Total Assets
710.6M
↓ 36.39%
Total Liabilities
344.0M
↓ 21.41%
FY23Y/Y Change
Total Assets
398.0M
↓ 43.99%
Total Liabilities
267.0M
↓ 22.36%
Q4 FY22Q/Q Change
Total Assets
710.6M
↓ 9.01%
Total Liabilities
344.0M
↓ 6.73%
Q1 FY23Q/Q Change
Total Assets
561.7M
↓ 20.95%
Total Liabilities
320.9M
↓ 6.71%
Q2 FY23Q/Q Change
Total Assets
494.3M
↓ 12.01%
Total Liabilities
297.3M
↓ 7.34%
Q3 FY23Q/Q Change
Total Assets
442.2M
↓ 10.53%
Total Liabilities
282.9M
↓ 4.86%
Q4 FY23Q/Q Change
Total Assets
398.0M
↓ 10.0%
Total Liabilities
267.0M
↓ 5.6%
Q1 FY24Q/Q Change
Total Assets
396.0M
↓ 0.51%
Total Liabilities
269.3M
↑ 0.85%
FY18Y/Y Change
Operating Cash Flow
718.2M
↓ 993.15%
Investing Cash Flow
-1.4B
↑ 4689.95%
Financing Cash Flow
852.0M
↑ 1466.37%
FY19Y/Y Change
Operating Cash Flow
-328.7M
↓ 145.76%
Investing Cash Flow
206.9M
↓ 114.99%
Financing Cash Flow
23.4M
↓ 97.26%
FY20Y/Y Change
Operating Cash Flow
-313.3M
↓ 4.68%
Investing Cash Flow
496.2M
↑ 139.85%
Financing Cash Flow
-80.4M
↓ 444.05%
FY21Y/Y Change
Operating Cash Flow
-412.7M
↑ 31.72%
Investing Cash Flow
202.8M
↓ 59.14%
Financing Cash Flow
36.2M
↓ 145.1%
FY22Y/Y Change
Operating Cash Flow
-304.0M
↓ 26.33%
Investing Cash Flow
365.8M
↑ 80.41%
Financing Cash Flow
1.5M
↓ 95.84%
Q4 FY22Q/Q Change
Operating Cash Flow
-57.7M
↓ 30.38%
Investing Cash Flow
40.0M
↓ 64.08%
Financing Cash Flow
103.0K
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-51.9M
↓ 10.03%
Investing Cash Flow
40.6M
↑ 1.46%
Financing Cash Flow
18.0K
↓ 82.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-51.5M
↓ 0.76%
Investing Cash Flow
25.2M
↓ 38.0%
Financing Cash Flow
18.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Nektar Therapeutics is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nektar Therapeutics
Nektar Therapeutics
26.27%
169.16%
155.6%
-91.56%
-95.6%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nektar Therapeutics
Nektar Therapeutics
NA
NA
3.22
-0.81
-0.96
-0.17
NA
0.69
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nektar Therapeutics
Nektar Therapeutics
Hold
$259.5M
-95.6%
NA
-195.02%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Nektar Therapeutics

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 24.14M → 21.63M (in $), with an average decrease of 5.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -137.01M → -36.80M (in $), with an average increase of 50.7% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 278.1%

Institutional Holdings

  • Deep Track Capital, LP

    10.00%

  • Vanguard Group Inc

    6.55%

  • Acadian Asset Management LLC

    4.11%

  • PRIMECAP Management Company

    3.79%

  • BlackRock Inc

    3.19%

  • Monaco Asset Management

    3.17%

Company Information

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Organization
Nektar Therapeutics
Employees
137
CEO
Mr. Howard W. Robin
Industry
Health Technology

Discover More

FAQs